An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 401–500 of 1,001
Bosma, R., Witt, G., Vaas, L. A. I., Josimovic, I., Gribbon, P. M., Vischer, H. F., Gul, S., & Leurs, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00667 · Cited by 35
Holenz, J., & Stoy, P. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.001 · Cited by 35
Modifying the lipophilic part of phenylthiazole antibiotics to control their drug-likeness
Hosny, Y., Abutaleb, N. S., Omara, M., Alhashimi, M., Elsebaei, M. M., Elzahabi, H. S. A., Seleem, M. N., & Mayhoub, A. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111830 · Cited by 35
Jiao, Y., Preston, S., Hofmann, A., Taki, A. C., Baell, J. B., Chang, B. C. H., Jabbar, A., & Gasser, R. B. (2020) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2019.12.003 · Cited by 35
Rao, M. S., McDuffie, E., & Sachs, C. W. (2023) · Toxics · doi:10.3390/toxics11100875 · Cited by 35
Zingman, I., Stierstorfer, B., Lempp, C., & Heinemann, F. (2023) · Medical Image Analysis · doi:10.1016/j.media.2023.103067 · Cited by 35
The landscape of the methodology in drug repurposing using human genomic data: a systematic review
Wang, L., Lü, Y., Li, D., Zhou, Y., Yu, L., Mesa‐Eguiagaray, I., Campbell, H. J., Li, X., & Τheodoratou, E. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbad527 · Cited by 35
Exposure-Based Validation of an In Vitro Gastrulation Model for Developmental Toxicity Assays
Warkus, E. L. L., & Marikawa, Y. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx034 · Cited by 35
Near‐Infrared Chemiluminescent Theranostics
Lin, Y., Huang, J., & Pu, K. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202501681 · Cited by 34
Epigenetic assays for chemical biology and drug discovery
Gul, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0342-6 · Cited by 34
Palabindela, R., Guda, R., Gondru, R., Myadaraveni, P., Banothu, D., Ravi, G., Korra, R., Mekala, H., & Kasula, M. (2022) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4488 · Cited by 34
Ghosh, S., Basu, S., Anbarasu, A., & Ramaiah, S. (2025) · Phytotherapy Research · doi:10.1002/ptr.8365 · Cited by 33
A rapid method for post-antibiotic bacterial susceptibility testing
Heller, A. A., & Spence, D. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210534 · Cited by 33
Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery
Huang, C.-T., Hsieh, C.-H., Chung, Y.-H., Oyang, Y.-J., Huang, H., & Juan, H. (2019) · iScience · doi:10.1016/j.isci.2019.04.039 · Cited by 33
Akao, Y., Canan, S. S., Cao, Y., Condroski, K. R., Engkvist, O., Itono, S., kaki, R., Kimura, C., Kogej, T., Nagaoka, K., et al. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00353k · Cited by 33
Self-citationLupăescu, A.-V., Iavorschi, M., & Covașă, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020235 · Cited by 33
Hirlekar, B. U., Nuthi, A., Singh, K. D., Murty, U. S., & Dixit, V. A. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115300 · Cited by 33
Virtual Cells: Predict, Explain, DiscoverPreprint
Noutahi, E., Hartford, J., Tossou, P., Whitfield, S., Denton, A. K., Wognum, C., Ulicna, K., Craig, M. J., Hsu, J., Cuccarese, M. F., et al. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2505.14613 · Cited by 33
Yi, J., Yang, Z., Zhao, W., Yang, Z., Zhang, X.-C., Wu, C., Lü, A., & Cao, D. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae008 · Cited by 32
Perspectives on the use of machine learning for ADME prediction at AstraZeneca
Gawehn, E., Greene, N., Miljković, F. N., Obrezanova, O., Subramanian, V., Trapotsi, M., & Winiwarter, S. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2352598 · Cited by 32
Challenges in validation of combination treatment strategies for CRC using patient-derived organoids
Benboubker, V., Ramzy, G. M., Jacobs, S., & Nowak-Sliwinska, P. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03173-x · Cited by 32
AI-Based Computational Methods in Early Drug Discovery and Post Market Drug Assessment: A Survey
Rajaei, F., Minoccheri, C., Wittrup, E. M., Wilson, R. C., Athey, B. D., Omenn, G. S., & Najarian, K. (2024) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2024.3492708 · Cited by 32
Tosi, U., Kommidi, H., Bellat, V., Marnell, C. S., Guo, H., Adeuyan, O. O., Schweitzer, M. E., Chen, N., Su, T., Zhang, G., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00607 · Cited by 32
Fang, H., Chen, L., & Knight, J. C. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30134-1 · Cited by 32
Striking essential oil: tapping into a largely unexplored source for drug discovery
Feyaerts, A. F., Luyten, W. H. M. L., & Dijck, P. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59332-5 · Cited by 32
Troup, R. I., Jeffries, B., Saudain, R. E. B., Georgiou, E., Fish, J., Scott, J. S., Chiarparin, E., Fallan, C., & Linclau, B. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c02810 · Cited by 32
Hallfors, N., Shanti, A., Sapudom, J., Teo, J. C. M., Petroianu, G. A., Lee, S., Planelles, L., & Stefanini, C. (2021) · Bioengineering · doi:10.3390/bioengineering8020019 · Cited by 32
Sebastiano, M. R., Ermondi, G., Hadano, S., & Caron, G. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.018 · Cited by 32
Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform
Guedj, M., Swindle, J., Hamon, A., Hubert, S., Desvaux, E., Laplume, J., Xuereb, L., Lefèbvre, C., Haudry, Y., Gabarroca, C., et al. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2095368 · Cited by 32
Unlocking the Potential of Generative Artificial Intelligence in Drug Discovery
Romanelli, V., Cerchia, C., & Lavecchia, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-46238-2_3 · Cited by 32
Fabre, K. M., Delsing, L., Hicks, R., Colclough, N., Crowther, D. C., & Ewart, L. C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.009 · Cited by 32
Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs
Gardiner, P., Cox, R. J., & Grime, K. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.087163 · Cited by 32
Weydert, Z., Lal‐Nag, M., Mathews-Greiner, L., Thiel, C., Cordes, H., Kuepfer, L., Guye, P., Kelm, J. M., & Ferrer, M. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219880194 · Cited by 32
Hartmann, J., Henschel, N., Bartmann, K., Dönmez, A., Brockerhoff, G., Koch, K., & Fritsche, E. (2023) · Cells · doi:10.3390/cells12091270 · Cited by 31
Advancing predictive toxicology: overcoming hurdles and shaping the future
Masarone, S., Beckwith, K. V., Wilkinson, M. R., Tuli, S., Lane, A., Windsor, S., Lane, J. S., & Hosseini-Gerami, L. (2025) · Digital Discovery · doi:10.1039/d4dd00257a · Cited by 31
Improving Small-Molecule Force Field Parameters in Ligand Binding Studies
Raniolo, S., & Limongelli, V. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.760283 · Cited by 31
The Role of Artificial Intelligence in Revolutionizing Pharmacological Research
Bhatia, N., Khan, M. M. U., & Arora, S. (2024) · Current Pharmacology Reports · doi:10.1007/s40495-024-00367-x · Cited by 31
The Opportunities of Metabolomics in Drug Safety Evaluation
Wang, P., Shehu, A. I., & Ma, X. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-016-0079-5 · Cited by 31
Chemogenetics a robust approach to pharmacology and gene therapy
Keifer, O. P., Kambara, K., Lau, A., Makinson, S., & Bertrand, D. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113889 · Cited by 31
Hoogstraten, C. A., Smeitink, J. A. M., Russel, F. G. M., & Schirris, T. J. J. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.842396 · Cited by 30
Applications of Organoids in Advancing Drug Discovery and Development
Gopallawa, I., Gupta, C., Jawa, R., Cyril, A., Jawa, V., Chirmule, N. B., & Gujar, V. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.06.016 · Cited by 30
Gadaleta, D., Serrano‐Candelas, E., Ortega-Vallbona, R., Colombo, E., de Lomana, M. G., Biava, G., Aparicio-Sánchez, P., Roncaglioni, A., Gozalbes, R., & Benfenati, E. (2024) · Journal of Cheminformatics · doi:10.1186/s13321-024-00931-z · Cited by 30
In Situ Target Engagement Studies in Adherent Cells
Axelsson, H., Almqvist, H., Otrocka, M., Vallin, M., Lundqvist, S., Hansson, P., Karlsson, U., Lundbäck, T., & Seashore-Ludlow, B. A. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b01079 · Cited by 30
Saavedra, L., Wallace, K., Freudenrich, T. M., Mall, M., Mundy, W. R., Davila, J., Shafer, T. J., Wernig, M., & Haag, D. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab008 · Cited by 30
Improving the assessment of the probability of success in late stage drug development
Hampson, L. V., Bornkamp, B., Holzhauer, B., Kahn, J., Lange, M. R., Luo, W., Cioppa, G. D., Stott, K., & Ballerstedt, S. (2021) · Pharmaceutical Statistics · doi:10.1002/pst.2179 · Cited by 30
The role of DMPK science in improving pharmaceutical research and development efficiency
Mak, K., Epemolu, O., & Pichika, M. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.005 · Cited by 30
Today’s drug discovery and the shadow of the rule of 5
Young, R. J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2228199 · Cited by 30
Vangala, S. R., Krishnan, S. R., Bung, N., Srinivasan, R., & Roy, A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00689 · Cited by 30
Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor
Bhattacharjee, D., Bakar, J., Chitnis, S. P., Sausville, E. L., Ashtekar, K. D., Mendelson, B. E., Long, K., Smith, J. C., Heppner, D. E., & Sheltzer, J. M. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.013 · Cited by 30
Torres, L. H. M., Ribeiro, B., & Arrais, J. P. (2024) · Applied Soft Computing · doi:10.1016/j.asoc.2024.111268 · Cited by 30
Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids
Hendriks, D. F. G., Hurrell, T., Riede, J., van der Horst, M., Tuovinen, S., & Ingelman-Sundberg, M. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz195 · Cited by 29
de Lamotte, J. D., Roquevière, S., Gautier, H. O. B., Raban, E., Bouré, C., Fonfría, E., Krupp, J., & Nicoleau, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.617867 · Cited by 29
Castellino, S., Lareau, N. M., & Groseclose, M. R. (2021) · Journal of Mass Spectrometry · doi:10.1002/jms.4717 · Cited by 29
The Chemical Space of Terpenes: Insights from Data Science and AI
Hosseini, M., & Pereira, D. M. (2023) · Pharmaceuticals · doi:10.3390/ph16020202 · Cited by 29
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
Wuelfing, W. P., Marrouni, A. E., Lipert, M. P., Daublain, P., Kesisoglou, F., Converso, A., & Templeton, A. C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01687 · Cited by 29
Artificial intelligence for antiviral drug discovery in low resourced settings: A perspective
Namba-Nzanguim, C. T., Turón, G., Simoben, C. V., Tietjen, I., Montaner, L. J., Efange, S. M. N., Duran‐Frigola, M., & Ntie‐Kang, F. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1013285 · Cited by 29
PharmGWAS: a GWAS-based knowledgebase for drug repurposing
Kang, H., Pan, S., Lin, S., Wang, Y., Yuan, N., & Jia, P. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad832 · Cited by 29
A Review of Recent Advances in Translational Bioinformatics: Bridges from Biology to Medicine
Vamathevan, J. J., & Birney, E. (2017) · Yearbook of Medical Informatics · doi:10.15265/iy-2017-017 · Cited by 29
Ferreira, S., Fisher, C., Furlong, L. I., Laplanche, L., Park, B. K., Pin, C., Sáez-Rodríguez, J., & Trairatphisan, P. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00499 · Cited by 29
LLM Agent Swarm for Hypothesis-Driven Drug DiscoveryPreprint
Song, K., Trotter, A., & Chen, J. Y. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2504.17967 · Cited by 29
Lin, Y., Wang, G., Li, Y., Yang, H., Zhao, Y., Liu, J., & Mu, L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad376 · Cited by 28
Rath, M. K., Wellnitz, J., Martin, H., Melo-Filho, C. C., Hochuli, J. E., Silva, G. M., Beasley, J.-M. T., Maxfield, T., Sessions, Z. L., Popov, K. I., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02446 · Cited by 28
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective
Johnstone, S., & Albert, J. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.084 · Cited by 28
Leveraging chromatography based physicochemical properties for efficient drug design
Goetz, G. H., & Shalaeva, M. Y. (2018) · ADMET & DMPK · doi:10.5599/admet.529 · Cited by 28
ZHENG, K. C., Li, A., Wu, W., Qian, S., Liu, B., & Pang, Q. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.07.102 · Cited by 28
The Screening Compound Collection: A Key Asset for Drug Discovery
Boss, C., Hazemann, J., Kimmerlin, T., von Korff, M., Lüthi, U., Peter, O., Sander, T., & Siegrist, R. (2017) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2017.667 · Cited by 28
Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology
Valentin, J., & Leishman, D. J. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105795 · Cited by 27
Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy
Bloomingdale, P., & Mager, D. E. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2562-7 · Cited by 27
Oliveira, E. A., Brito, I. A., Lima, M. L., Romanelli, M. M., Moreira‐Filho, J. T., Neves, B. J., Andrade, C. H., Sartorelli, P., Tempone, A. G., Costa‐Silva, T. A., et al. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00890 · Cited by 27
Organ-on-a-Chip for Drug Screening: A Bright Future for Sustainability? A Critical Review
Feitor, J. F., Brazaca, L. C., Lima, A. M., Ferreira, V. G., Kassab, G., Bagnato, V. S., Carrilho, E., & Cardoso, D. R. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01454 · Cited by 27
Mavroudis, P. D., Teutonico, D., Abós, A., & Pillai, N. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1180948 · Cited by 27
Target Safety Assessment: Strategies and Resources
Brennan, R. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7172-5_12 · Cited by 27
Hevener, K. E. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7899-1_13 · Cited by 27
Testing for drug-human serum albumin binding using fluorescent probes and other methods
Ronzetti, M. H., Baljinnyam, B., Yasgar, A., & Simeonov, A. M. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1534824 · Cited by 27
Safety biomarker applications in drug development
Schomaker, S., Ramaiah, S. K., Khan, N., & Burkhardt, J. E. (2019) · The Journal of Toxicological Sciences · doi:10.2131/jts.44.225 · Cited by 27
Repurposed Molecules: A New Hope in Tackling Neglected Infectious Diseases
Fernandez‐Prada, C., Douanne, N., Minguez-Menendez, A., Pena, J., Tunes, L. G., Pires, D. E. V., & do Monte‐Neto, R. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00005-5 · Cited by 27
Advances in machine learning for optimizing pharmaceutical drug discovery
Ogbonna, U. E., Ofoezie, E. F., Babalola, O. O., Ottu, P. O., Ogbonna, C. A., Olisakwe, S. C., George, E. T., Babarinde, S., Omaba, O. J., Chukwuemeka, C. G., et al. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100015 · Cited by 26
Reprogramming of antibiotics to combat antimicrobial resistance
Dubey, K. K., Indu, & Sharma, M. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000168 · Cited by 26
Long, M. J. C., Rogg, C., & Aye, Y. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00537 · Cited by 26
Fleck, N., Roschangar, F., & Haydl, A. M. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00037 · Cited by 26
Early phase clinical trials in oncology: Realising the potential of seamless designs
Jaki, T., Burdon, A., Chen, X., Mozgunov, P., Zheng, H., & Baird, R. D. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.005 · Cited by 26
Xu, C., Zhang, X., Zhao, L., Verkhivker, G. M., & Bai, F. (2024) · JACS Au · doi:10.1021/jacsau.4c00123 · Cited by 26
Dunnington, E. L., Wong, B. S., & Fu, D. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01413 · Cited by 26
Occurrence of “Natural Selection” in Successful Small Molecule Drug Discovery
Heinzke, A. L., Pahl, A., Zdrazil, B., Leach, A. R., Waldmann, H., Young, R. J., & Leeson, P. D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00811 · Cited by 26
Self-citationVarney, A. M., Smitten, K. L., Thomas, J. A., & McLean, S. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00159 · Cited by 26
Regulatory pitfalls and opportunities when repurposing for inhalation therapy
Lyapustina, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.013 · Cited by 26
The Next Frontier: Unveiling Novel Approaches for Combating Multidrug-Resistant Bacteria
Mallari, P., Rostami, L. D., Alanko, I., Howaili, F., Ran, M., Bansal, K. K., Rosenholm, J. M., & Salo‐Ahen, O. M. H. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03871-x · Cited by 25
Sequence-based virtual screening using transformers
Zhang, S., Huo, D., Horne, R. I., Qi, Y., Ojeda, S. P., Yan, A., & Vendruscolo, M. (2025) · Nature Communications · doi:10.1038/s41467-025-61833-8 · Cited by 25
The Convergence of Artificial Intelligence and Microfluidics in Drug Research and Development
Qiao, D., Li, H., Zhang, X., Chen, X., Jiang, Z., Zou, J., Zhao, D., Zhu, W., Qian, X. H., & Li, H. (2025) · Engineering · doi:10.1016/j.eng.2025.07.025 · Cited by 25
Naga, D., Muster, W., Musvasva, E., & Ecker, G. F. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-022-00603-w · Cited by 25
Barua, R., Biswas, N., & Das, D. (2024) · Advances in healthcare information systems and administration book series · doi:10.4018/979-8-3693-1214-8.ch010 · Cited by 25
Bowling, P. E., Broderick, D. R., & Herbert, J. M. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.4c01429 · Cited by 25
Computational Toxicology and Drug Discovery
Hasselgren, C., & Myatt, G. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7899-1_11 · Cited by 25
Ono, A., Matsumura, N., Kimoto, T., Akiyama, Y., Funaki, S., Tamura, N., Hayashi, S., Kojima, Y., Fushimi, M., Sudaki, H., et al. (2019) · ADMET & DMPK · doi:10.5599/admet.704 · Cited by 25
Fu, A., Peh, Y. M., Ngan, W., Wei, N., & Luo, K. Q. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26816 · Cited by 25
Advances in Nanomedicine Drug Delivery Applications for HIV Therapy
Curley, P., Liptrott, N. J., & Owen, A. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0069 · Cited by 25
In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach
Ciallella, J. R., & Reaume, A. G. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.04.001 · Cited by 24
NMR spectroscopy in drug discovery and development: Evaluation of physico-chemical properties
Zloh, M. (2019) · ADMET & DMPK · doi:10.5599/admet.737 · Cited by 24
Qing, L., Wang, T., Luo, H.-Y., Du, J.-L., Wang, R.-Y., & Luo, P. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116832 · Cited by 24
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities
Rudd, S. G. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04562-3 · Cited by 24
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.